Drug Therapy

Immunotherapy is a new type of experimental cancer treatment that is viewed by many to have possible applications in the treatment of mesothelioma, a rare asbestos cancer that has thus far proven to be incurable.

Clinical trials are oftentimes associated with the research and development of new drugs; however, clinical trials are used to test out a variety of new techniques, treatments, products, etc.

What are Antineoplastons?

Antineoplastons were isolated by Stanislaw R. Burzynski, M.D. more than 20 years ago to be used as a type of unique cancer treatment (in addition to fighting HIV infection and certain autoimmune diseases). Antineoplastons are a group of 120 peptide fragments, amino acid derivatives and organic acids that are found to occur naturally throughout the body; however, antineoplastons can also be manufactured synthetically in a laboratory. Derived from glutamine, phenylacetate salts and isoglutamine, antineoplastons are the subject of a great deal of controversy within the medical community.

Dr. Burzynski has been working with antineoplastons as a treatment for cancer since the late 1960s. He believes that spontaneous regression of cancerous cells is caused by anticancer peptides that are found in large quantities throughout the blood and urine. Based on this, Burzynski states that the application of antineoplastons could be capable of "normalizing" cancer cells by reprogramming certain errors in cellular differentiation.

Two antineoplastons that are commonly used by Burzynski in his research are A10 (phenylacetylisoglutamine and phenylacetylglutamine [PAG] in a mixture ratio of 1:4) and AS2-1 (PAG and phenylacetic acid in a mixture ratio of 1:4). Burzynski has used the aforementioned antineoplastons in the experimental treatment of patients suffering from recurrent anaplastic astrocytoma (nervous system tumor), glioblastoma multiforme (malignant brain tumor) and malignant mesothelioma.